We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer and BMS's Eliquis Gets FDA Nod for Third Indication

Pfizer and BMS's Eliquis Gets FDA Nod for Third Indication

August 28, 2014

Pfizer and Bristol-Myers Squibb’s blood thinner Eliquis won a new indication for the treatment of blood clots deep in the legs and lungs.

The FDA approval was based on a global study of roughly 5,244 patients with confirmed symptomatic deep vein thrombosis and pulmonary embolism who were given either Eliquis (apixaban) or the existing standard of care, Lovenox (enoxaparin) and warfarin.

While Eliquis showed comparable efficacy against recurrent, symptomatic DVT or PE, it proved to be superior to standard of care in reducing incidents of major bleeding in critical areas, including fatal bleeding, Pfizer spokeswoman Jennifer Kokell said.

This is the third indication for the drug, which also is approved to reduce the risk of stroke and blood clots in patients with irregular heart rhythms, and as a preventive treatment of deep vein thrombosis, which may lead to blood clots in the lungs of patients who have undergone hip or knee replacement surgery.

Eliquis comes with a hefty set of boxed warnings. Patients who stop taking the oral therapy early, for example, are at increased risk of blood clotting. Patients who undergo epidural anesthesia or spinal puncture may end up with epidural or spinal hematoma, potentially ending in paralysis. A third warning is for potentially fatal bleeding.

The drug was first approved in 2012. It also has received the latest indication in the European Union, Kokell said. Eliquis garnered $171 million in sales in the second quarter of 2014, according to BMS. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing